551943-84-1

Basic information

• Product Name: (S)-2-Phenyl-2-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-ethanol
• CAS NO: 551943-84-1
• Molecular Weight: 360.477
• Mol File: 551943-84-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-Phenyl-2-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-Phenyl-2-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-ethanol(551943-84-1)
• EPA Substance Registry System: (S)-2-Phenyl-2-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-ethanol(551943-84-1)

Safety Data

• Hazardous Substances Data: 551943-84-1(Hazardous Substances Data)

Upstream product

• 52601-81-7 4-Methyl-N,N-bis<2-(methylsulfonyloxy)ethyl>benzolsulfonamid 
• 20989-17-7 (2S)-2-phenylglycinol 

Downstream Products

• 551943-85-2 3,5-Bis-trifluoromethyl-benzoic acid (S)-2-phenyl-2-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-ethyl ester 
• 346417-35-4 1-{(S)-2-[(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-1-phenyl-ethyl}-piperazine 
• 551943-94-3 1-{(S)-2-[(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-1-phenyl-ethyl}-piperazine 
• 346417-69-4 2-(4-{(S)-2-[(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-1-phenyl-ethyl}-piperazin-1-yl)-acetamide 
• 346417-70-7 2-(4-{(S)-2-[(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-1-phenyl-ethyl}-piperazin-1-yl)-acetamide 
• 346415-25-6 2-[2-(4-{(S)-2-[(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-1-phenyl-ethyl}-piperazin-1-yl)-ethoxy]-acetamide 
• 346417-73-0 2-[2-(4-{(S)-2-[(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-1-phenyl-ethyl}-piperazin-1-yl)-ethoxy]-acetamide 
• 551943-87-4 1-{(S)-2-[1-(3,5-Bis-trifluoromethyl-phenyl)-vinyloxy]-1-phenyl-ethyl}-4-(toluene-4-sulfonyl)-piperazine 

Relevant articles and documents

Dual NK1 antagonists - Serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives

The synthesis, structure-affinity relationship and activity of benzyloxyphenethyl piperazine derivatives combining NK1 antagonism and serotonin reuptake inhibition is described. Compound 7u was shown to be active in animal models of 5-HT reuptake inhibition and central NK1 receptor blockade, and was demonstrated to be orally active in an integrated model sensitive to both mechanisms. This class of compounds potentially represents a new generation of antidepressants.